Methods for reducing migraine frequency in a subject in need thereof
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorRami Burstein
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
Claims18
A method for reducing migraine frequency in a subject suffering from chronic or episodic migraine comprising administering to the subject an antibody or antigen-binding fragment thereof that blocks, inhibits, suppresses, or reduces the calcitonin gene related peptide (CGRP) pathway, wherein the antibody or antigen-binding fragment thereof is an anti-CGRP antagonist antibody or an anti-CGRP receptor antibody, thereby reducing migraine frequency in the subject, wherein, prior to administration of the antibody or antigen-binding fragment thereof, the subject is known to exhibit allodynia and/or hyperalgesia during an acute phase of a migraine but not during an interictal phase of the migraine.
A method for reducing migraine frequency in a subject suffering from chronic or episodic migraine comprising:
- a) determining whether the subject exhibits allodynia and/or hyperalgesia during the interictal phase of a migraine, and
- b) administering an antibody or antigen-binding fragment thereof that blocks, inhibits, suppresses, or reduces the calcitonin gene related peptide (CGRP) pathway to the subject that does not exhibit signs of allodynia and/or hyperalgesia during the interictal phase of the migraine;
- wherein the antibody or antigen-binding fragment thereof is an anti-CGRP antagonist antibody or an anti-CGRP receptor antibody.
Dependencies are inferred from the claim text.